ADRB3 and overactive bladder: However, the development of the new selective β3-AR agonist, mirabegron, and its approval by health authorities for the treatment of overactive bladder disease [90] led to new pilot clinical trials assessing BAT stimulation following acute or more chronic treatment with this drug.